TNF-inhibitors or bisphosphonates in chronic nonbacterial osteomyelitis? - Results of an international retrospective multicenter study

TNF-inhibitors or bisphosphonates in chronic nonbacterial osteomyelitis? - Results of an international retrospective multicenter study

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 238(2022) vom: 01. Mai, Seite 109018
1. Verfasser: Schnabel, A (VerfasserIn)
Weitere Verfasser: Nashawi, M, Anderson, C, Felsenstein, S, Lamoudi, M, Poole-Cowley, J, Lindell, E, Oates, B, Fowlie, P, Walsh, J, Ellis, T, Hahn, G, Goldspink, A, Martin, N, Mahmood, K, Hospach, T, Lj, McCann, Hedrich, C M
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Multicenter Study Bone CNO CRMO Chronic nonbacterial osteomyelitis Pamidronate Response TNF inhibitor Treatment mehr... Diphosphonates Tumor Necrosis Factor Inhibitors OYY3447OMC
LEADER 01000naa a22002652 4500
001 NLM339900296
003 DE-627
005 20231226003926.0
007 cr uuu---uuuuu
008 231226s2022 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2022.109018  |2 doi 
028 5 2 |a pubmed24n1132.xml 
035 |a (DE-627)NLM339900296 
035 |a (NLM)35460903 
035 |a (PII)S1521-6616(22)00099-7 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Schnabel, A  |e verfasserin  |4 aut 
245 1 0 |a TNF-inhibitors or bisphosphonates in chronic nonbacterial osteomyelitis? - Results of an international retrospective multicenter study 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 17.05.2022 
500 |a Date Revised 20.05.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. 
520 |a Chronic nonbacterial osteomyelitis (CNO) can cause significant morbidity, including bone pain and damage. In the absence of clinical trials, treatments include non-steroidal anti-inflammatory drugs, corticosteroids, TNF-inhibitors (TNFi) and/or bisphosphonates. In a retrospective chart review in the United Kingdom and Germany, we investigated response to TNFi and/or pamidronate. Ninety-one patients were included, receiving pamidronate (n = 47), TNFi (n = 22) or both sequentially (n = 22). Patients with fatigue [p = 0.003] and/or arthritis [p = 0.002] were more frequently treated with TNFi than pamidronate. Both therapies were associated with clinical remission at 6 months, and reduction of bone lesions on MRI at 12 months. While not reaching statistical significance, pamidronate resulted in faster resolution of MRI lesions. Fewer flares were observed with TNFi. Failure to respond to pamidronate was associated with female sex [p = 0.027], more lesions on MRI [p = 0.01] and higher CRP levels [p = 0.03]. Randomized clinical trials are needed to confirm observations and generate evidence 
650 4 |a Journal Article 
650 4 |a Multicenter Study 
650 4 |a Bone 
650 4 |a CNO 
650 4 |a CRMO 
650 4 |a Chronic nonbacterial osteomyelitis 
650 4 |a Pamidronate 
650 4 |a Response 
650 4 |a TNF inhibitor 
650 4 |a Treatment 
650 7 |a Diphosphonates  |2 NLM 
650 7 |a Tumor Necrosis Factor Inhibitors  |2 NLM 
650 7 |a Pamidronate  |2 NLM 
650 7 |a OYY3447OMC  |2 NLM 
700 1 |a Nashawi, M  |e verfasserin  |4 aut 
700 1 |a Anderson, C  |e verfasserin  |4 aut 
700 1 |a Felsenstein, S  |e verfasserin  |4 aut 
700 1 |a Lamoudi, M  |e verfasserin  |4 aut 
700 1 |a Poole-Cowley, J  |e verfasserin  |4 aut 
700 1 |a Lindell, E  |e verfasserin  |4 aut 
700 1 |a Oates, B  |e verfasserin  |4 aut 
700 1 |a Fowlie, P  |e verfasserin  |4 aut 
700 1 |a Walsh, J  |e verfasserin  |4 aut 
700 1 |a Ellis, T  |e verfasserin  |4 aut 
700 1 |a Hahn, G  |e verfasserin  |4 aut 
700 1 |a Goldspink, A  |e verfasserin  |4 aut 
700 1 |a Martin, N  |e verfasserin  |4 aut 
700 1 |a Mahmood, K  |e verfasserin  |4 aut 
700 1 |a Hospach, T  |e verfasserin  |4 aut 
700 1 |a Lj, McCann  |e verfasserin  |4 aut 
700 1 |a Hedrich, C M  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 238(2022) vom: 01. Mai, Seite 109018  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:238  |g year:2022  |g day:01  |g month:05  |g pages:109018 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2022.109018  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 238  |j 2022  |b 01  |c 05  |h 109018